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Abstract
Objectives
Primary study outcome was absence of treatment failure (virological failure, VF, or treat-
ment interruption) per protocol at week 48.
Methods
Patients on 3-drug ART with stable HIV-1 RNA <50 copies/mL and CCR5-tropic virus were
randomized 1:1 to maraviroc with darunavir/ritonavir qd (study arm) or continue current ART
(continuation arm).
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Results
In June 2015, 115 patients were evaluable for the primary outcome (56 study, 59 continua-
tion arm). The study was discontinued due to excess of VF in the study arm (7 cases,
12.5%, vs 0 in the continuation arm, p = 0.005). The proportion free of treatment failure was
73.2% in the study and 59.3% in the continuation arm. Two participants in the study and 10
in the continuation arm discontinued therapy due to adverse events (p = 0.030). At VF, no
emergent drug resistance was detected. Co-receptor tropism switched to non-R5 in one
patient. Patients with VF reported lower adherence and had lower plasma drug levels. Fem-
oral bone mineral density was significantly improved in the study arm.
Conclusion
Switching to maraviroc with darunavir/ritonavir qd in virologically suppressed patients was
associated with improved tolerability but was virologically inferior to 3-drug therapy.
Introduction
Antiretroviral therapy (ART) significantly reduces morbidity and mortality associated with
HIV infection; this is best achieved by chronically maintaining undetectable levels of HIV-1
RNA in patients plasma [1]. The combination of three active agents in the first-line regimen is
the standard of care to achieve this virological goal and nucleoside reverse transcriptase inhibi-
tors (NRTIs) are the essential component of all initial treatment strategies [2–4].
The long-term side effects of NRTIs are still of concern. Some agents are associated with
renal and bone toxicity [5–7], others with increased rates of cardiovascular events [8]. There-
fore, several attempts have been performed in order to test NRTI-sparing maintenance therapy
in virologically controlled individuals [9–12]. Maraviroc is the only CCR5 (R5) co-receptor
antagonist approved for use in patients carrying an R5-tropic virus [13]. Currently, the drug is
approved only for patients failing previous regimens, given its inferior efficacy as initial ther-
apy [14–16]. Nonetheless, agents with this mechanism of action should ideally be used early
during treatment, before the possible switch from R5 to non-R5 tropism at later stages [17].
The efficacy of maraviroc as maintenance therapy in virologically controlled patients has
been recently tested in the MARCH study [18]. In this large randomized study enrolling viro-
logically controlled patients on 2 NRTIs plus a boosted protease inhibitor (bPI), substitution of
NRTIs with maraviroc twice daily was inferior to continuing the baseline 3-drug regimen. One
obstacle to the implementation of this strategy, the requirement of viral tropism testing in
patients with suppressed viremia, has been overcome by genotypic tropism testing on viral
DNA [19]. This strategy has now been validated retrospectively [20–21] as well as prospectively
[18]. The MARCH study was limited as the switch to maraviroc included patients with boosted
PI from older generations that were in most cases administered twice daily. Also, maraviroc
was used twice daily, which lacks convenience in terms of dosing and cost.
The aim of this study was to test non-inferiority of an NRTI-sparing dual therapy based on
once daily maraviroc with darunavir/ritonavir as compared to continuing an ongoing, virolog-
ically successful 3-drug therapy. The experimental regimen tested here is not according to the
label of maraviroc. A secondary aim was to perform a prospective validation of selecting
patients with R5 virus based on single-sequence viral DNA genotyping [22].
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Methods
Study design, inclusion and exclusion criteria
GUSTA (GUided Simplification with Tropism Assay) was a multicenter, open-label, ran-
domized study (registered at www.clinicaltrials.gov, number NCT01367210). The study pro-
tocol was authorized by the Italian Drug Regulatory Agency (AIFA) and approved by the
local Ethics Committees at each study center; written informed consent was obtained from
all patients before participation. The study was performed in accordance with the ethical
guidelines of the Declaration of Helsinki (7th revision) and with the International Confer-
ence on Harmonization Good Clinical Practice guidelines. The authors confirm that all
related trials for this intervention are registered. Study approval by the Ethics Committee of
the Catholic University was obtained on November 18, 2010. Between May 23, 2011 and
April 22, 2015, patients underwent screening for the study and the latest visit was on Septem-
ber 28, 2015. The complete list of Ethics Committes that approved study is: Ethics Committee
of Umbria and Perugia; Ethics Committee of Azienda Ospedaliera Sacco, Milan; Ethics Com-
mittee of Modena; Ethics Committee Azienda Ospedaliero-Universitaria of Florence; Ethics
Committee University of Study D’Annunzio and Chieti; Ethics Committee AUSL 9 of Gros-
seto; Ethics Committee Azienda Ospedaliera Universitaria S Martino, Genova; Ethics Com-
mittee AUSL 3 Pistoia; Ethics Committee Azienda Ospedaliera S. Salvatore of Pesaro; Ethics
Committee AOU San Luigi Gonzaga of Orbassano; Ethics Committee Azienda Ospedaliero-
Universitaria Policlinico S. Orsola-Malpighi of Bologna; Ethics Committee IRCC of Rome;
Ethics Committee of Lecce; Ethics Committee Policlinico Umberto I of Rome; Ethics Com-
mittee Lazio 2; Ethics Committee IRCC Spallanzani of Rome; Ethics Committee San Paolo
Hospital, Milano.
Eligible patients were HIV-1-infected, aged18 years, treated with any ART regimen
including 3 drugs without treatment changes during the last 3 months, with HIV-1 RNA <50
copies/mL for at least 6 months on two consecutive determinations, with CD4 cell count>200
cells/mm3 for at least 3 months, and with R5 virus.
Main exclusion criteria were having a CD4 cell count at nadir <50 cell/mm3 or <100 cell/
mm3 in case of a history of virological failure with PI, past use of maraviroc, pregnancy, breast-
feeding status, positive serum hepatitis B virus surface antigen, a history of major toxicity to
any of the study or current drugs, AIDS-related events in the year before screening, liver cir-
rhosis, eGFR<30 mL/min and grade IV ALT or AST elevation. Previous virological failures
were allowed, but previous failures to enfuvirtide or integrase inhibitors and patients with at
least one major or two minor darunavir resistance mutations (last available IAS-USA list) were
excluded.
Determination of viral tropism and resistance testing
All patients underwent genotypic testing for HIV-1 coreceptor tropism at screening by pop-
ulation sequencing on whole blood using a single DNA sequence of the gp120 V3 env region
[22]. DNA sequence retesting was allowed a maximum of three times in case of amplifica-
tion failure. Results were interpreted using the geno2pheno prediction algorithm. A false
positive rate (FPR) higher than 10% indicated an R5 virus. The genotyping was performed
at virological laboratories that had been certified by a national QC/QA program for geno-
typic tropism determination [23]. The genotypic HIV-1 coreceptor tropism assay has been
deposited in the protocols.io repository with doi 10.17504/protocols.io.jmnck5e. Genotypic
resistance to NRTIs, NNRTIs and PIs was determined using the Viroseq HIV-1 Genotyping
System.
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Study procedures
At baseline, eligible patients were randomized 1:1 to receive maraviroc 300 mg qd (except
those with glomerular filtration rate, eGFR, <80 mL/min who received 150 mg qd) plus daru-
navir/ritonavir 800/100 mg (study, S, arm) or to continue the previous antiretroviral regimen
(continuation, C, arm). Follow-up visits were scheduled at weeks 4, 12 and every 12 weeks
thereafter. Routine physical examination and laboratory tests, including CD4 cell counts and
HIV-1 RNA levels, were performed at baseline and at each follow-up visit.
Efficacy and safety outcomes definition and handling
Treatment failure was defined as any of the following: virological failure, discontinuation or
change of any current drug due to any cause, withdrawal of consent after treatment initiation,
loss to follow-up, progression to AIDS or death. Virological failure was defined as the second
of two consecutive HIV-1 RNA levels >50 copies/mL or a single HIV-1 RNA level>1,000
copies/mL. At the time of virological failure, an additional visit and blood sampling were
performed. Clinical and laboratory adverse events occurring during the study were graded
according to the latest available Division of AIDS tables. A Data Safety Monitoring Board was
established to monitor patient safety and treatment efficacy data.
Study endpoints and sample size calculation
The primary study endpoint was the proportion of patients free of treatment failure at 48
weeks on the per-protocol population. Based on the assumption that 90% of patients in the
continuation arm would meet the primary outcome, enrolment of 330 patients distributed 1:1
in each study arm was planned in order to test non-inferiority of the study arm with a lower
bound of 10%, a confidence interval of 95% and a power of 80%. Secondary endpoints were:
the proportion of patients with treatment failure and virological failure at 48 weeks on the
intention-to-treat population, modification of CD4 cell count and of blood metabolic parame-
ters, changes in bone parameters, self-reported adherence and symptoms scores, and of
health-related Quality of Life from baseline to week 48.
Evaluation of bone mineral density
At baseline and at week 48, patients from 7 study sites underwent dual-energy X-ray absorpti-
ometry scans to analyze bone mineral density (BMD) (Hologic Inc., Waltham, MA, USA).
Total L2–L4 lumbar column and femoral neck BMD were recorded. Moreover, plasma alka-
line phosphatase (total and bone-associated), 25(OH)vitamin D, parathyroid hormone (PTH)
and osteocalcin were measured.
Plasma drug levels, adherence, patient-reported symptoms and quality
of life
Plasma drug levels were measured in arm S in blood collected before morning antiretroviral
drug intake between week 4 and 48 by a validated tandem mass spectrometry (UPLC-MS/
MS). The time of the last drug intake and of blood sampling were recorded for each patient
and Ctrough were calculated accordingly using the formula C = C0 × e-kt (C = calculated trough
levels; C0 = at the time measured; K = elimination rate consant (0.693/t1/2); e = base of natural
logaritm). Liquid/liquid extraction was employed for purification and concentration of mara-
viroc, darunavir and ritonavir from plasma samples. Samples were injected into an AQUITY
UPLC system employing an AQUITY UPLC BEH C18 column (Waters Corp., Milford, MA,
USA) for analysis. The UPLC was connected to a triple quadrupole tandem mass detector
Switch to maraviroc with darunavir/r
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(Waters Corp., Milford, MA, USA) for the mass spectrometric detection. Data were processed
using MassLynx with a QuanLynx program version 4.1 (Waters Corp., Milford, MA, USA).
The detection limit for the drug determination was 30 ng/mL. We computed Ctrough when
maraviroc levels were available 6–27 hours after intake and darunavir 10–27 hours after intake,
i.e. during the linear phase of the elimination curve. All patients were instructed to take the
study medications with food. In both arms, self-reported adherence (weeks 0, 4, 24 and 48),
patient-reported symptoms and physical/mental Quality of Life (QoL) scores (weeks 0 and 48)
were collected using validated questionnaires [24, 25]. Self-reported adherence was recorded
as indicated on a 0–100 visual analogue scale (VAS). Both physical and mental health-related
QoL were assessed on a 0–100 VAS scale (0 = worst level; 100 = best level). In addition, the
questionnaire included a list of 32 common self-reported symptoms, which were graded
between 0 (absent) and 5 (very intense): mean values of symptoms were compared between
study arms.
Statistical analysis
Descriptive statistics were used to describe baseline patients characteristics, main study out-
comes, laboratory toxicities, clinical adverse events and serious adverse events. Differences
between categorical variables were tested by the Chi-square test, differences between continu-
ous variables were tested using the t-test or the Mann-Whitney U test, as appropriate. Changes
from baseline values at week 48 were assessed using Student’s t-test for paired samples. The
primary efficacy endpoint, treatment failure, was investigated by per-protocol (PP) analysis at
study week 48: this analysis excluded patients with major protocol violations. In addition, an
intention-to-treat (ITT) analysis at study week 48 including all randomized patients who
received at least one drug dose after randomization was also performed. In all the mentioned
analyses on treatment failure, missing values and those who had changed or discontinued their
ART regimen were counted as failures. In a further secondary analysis, time to virological fail-
ure was also analysed in all randomized patients divided by study arm, until last available fol-
low-up at the time of study interruption, using the Kaplan-Meier method. Non-inferiority for
the primary outcome was tested using the one-sided test procedure: noninferiority would be
established at an alpha level of 0.05 if the dual therapy arm achieved the primary outcome in
no more than 10% less patients than the current therapy arm.
A two tailed P value <0.05 was considered to be statistically significant. All analyses were
performed using the SPSS version 22 software package (IBM, SPSS, Chicago, IL, USA, IBM).
Results
Patient characteristics at baseline
Between May 23, 2011 and April 22, 2015, 259 patients underwent screening for the study. On
June 2015, based on a pre-planned 48-week interim analysis, the Data Safety Monitoring
Board recommended trial discontinuation due to an excess of virological failures in the study
arm. At that time, screening failures were 89/259 (36%): 67 (26%) for non-R5 viral tropism, 11
(4%) for HIV-RNA >50 copies/mL, 6 (2%) for V3 region of HIV-1 gp120 not amplifiable, 5
(2%) due to other exclusion criteria. Five (2%) additional patients were excluded due to con-
sent withdrawal before randomization. Therefore, 165 patients were randomized of whom 123
were evaluable for the 48-weeks ITT analysis (62 in arm S and 61 in arm C), and 115 were
included in the main PP analysis (56 in arm S and 59 in arm C) (Fig 1).
The main baseline characteristics of the PP study population, overall and divided by study
arm, are summarized in Table 1, while the respective details for the ITT population are sum-
marized in S1 Table.
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Main study outcomes: Treatment and virological failure
In the PP population, 76/115 (66%) patients were free of treatment failure at 48 weeks: 41/56
(73.2%) in arm S and 35/59 (59.3%) arm C (Fig 2a). The proportion free of treatment failure in
arm S was noninferior to the proportion in arm C (S minus C arm +13.9%; 95%, CI -0.6;
+28.4, p = 0.058). Detailed reasons of treatment failures are shown in Table 2. Seven protocol-
defined virological failures occurred in arm S (12.5%) and none in arm C (p = 0.005). Two
patients (3.6%) in arm S and 10 (16.9%) in arm C discontinued therapy owing to adverse
events (p = 0.030).
In the ITT population the proportion free of treatment failure at 48 weeks in arm S was
noninferior to the proportion in arm C (S arm minus C arm +11.9%; 95%CI -2.1; +25.9,
p = 0.080) (Fig 2b). All 8 protocol-defined virological failures in the ITT population occurred
in arm S. Virological blips without protocol-defined virological failure occurred in seven
patients in arm S, and four in arm C. In 7 of 7 successfully genotyped patients no resistance-
associated mutation was detected in the reverse transciptase and protease region, viral tropism
remained R5 in 6 of 6 succesfully genotyped viral RNA samples and in 7 of 8 DNA samples (1
patient harbored a non-R5 virus with a FPR of 0.5%, RNA genotyping of this case was repeat-
edly unsuccessful). Four to 8 weeks after virological failure HIV-1 RNA was<50 copies/mL
Fig 1. GUSTA flow diagram.
https://doi.org/10.1371/journal.pone.0187393.g001
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without any treatment change in one patient and after switching to a triple therapy in the
remaining seven.
When baseline characteristics of the 8 patients with virological failure in arm S (ITT popu-
lation) were compared with the 54 without virological failure in the same arm, significant dif-
ferences included a higher mean baseline FPR of the geno2pheno co-receptor assay (67% vs
42%, p = 0.015), a shorter duration of previous virological suppression (37 vs 61 months,
p = 0.057) in those with virological failure as compared to those without. Other characteristics
(CD4 cell count at nadir and at baseline, time from HIV diagnosis or from first cART initia-
tion, cART drugs at screening and HCV status) did not differ between patients with virological
failure and those without (S2 Table). In a further analysis we described the time to virological
failure using the complete follow-up available until the time of study interruption. While there
were no failures in arm C, the mean time to virological failure in arm S was 30 weeks (95% CI
19–42) (Fig 3).
Table 1. Baseline patients characteristics of the per-protocol population.
Total n = 115 DRV/r + MVC (Arm S) n = 56 3-drug ART (Arm C) n = 59 P-value (between arms)
Age, years* 49 (41–57) 51 (44–59) 48 (40–55) 0.109
Male gender 86 (75) 43 (77) 43 (73) 0.630
Caucasian ethnicity 104 (90) 50 (89) 54 (91) 0.280
Risk factor: 0.223
Heterosexual 46 (40) 24 (43) 22 (37)
Homo/bisexual 40 (35) 20 (36) 20 (34)
Past injecting drug user 11 (9) 7 (12) 4 (7)
Other/unknown 18 (16) 5 (9) 13 (22)
HCV co-infection 16 (14) 9 (16) 7 (12) 0.322
Years from HIV diagnosis* 12 (7–18) 14 (7–19) 11 (7–17) 0.237
Years from first ART initiation* 10 (6–16) 10 (6–16) 10 (6–15) 0.610
Months from last regimen initiation* 51 (34–69) 51 (36–70) 50 (29–64) 0.324
Months from last HIV-RNA >50 cp/mL** 59 (52–65) 59 (51–68) 58 (49–67) 0.824
CD4 nadir, cells/μL* 222 (137–310) 214 (108–314) 222 (139–304) 0.765
CD4, cells/μL* 659 (495–923) 640 (494–992) 690 (494–908) 0.688
Treatment at screening:
NRTI 109 (95) 51 (91) 58 (98) 0.081
TDF 70 (61) 31 (55) 39 (66) 0.238
NNRTI 22 (19) 9 (16) 13 (22) 0.416
InSTI 22 (19) 11 (17.7) 11 (19) 0.892
PI 68 (59) 36 (64) 32 (54) 0.273
Boosted PI 57 (50) 30 (54) 27 (46) 0.403
DRV/r 30 (26) 14 (25) 16 (27) 0.796
QD regimen at screening 72 (63) 34 (61) 38 (64) 0.074
Results are expressed as n (%),
*median (IQR) or
** mean (95% CI).
Abbreviations legend: DRV/r, darunavir/ritonavir; MVC, maraviroc; ART, antiretroviral therapy; TDF/FTC, tenofovir/emtricitabine; HCV, hepatitis C virus; PI,
protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; InSTI, Integrase strand transfer
inhibitors; QD, once daily
https://doi.org/10.1371/journal.pone.0187393.t001
Switch to maraviroc with darunavir/r
PLOS ONE | https://doi.org/10.1371/journal.pone.0187393 November 21, 2017 7 / 18
Clinical and laboratory events
During the 48 weeks of the study 78 clinical adverse events were observed in 49 of the 123
patients (ITT population, S3 Table). Eleven were classified as serious adverse events: 6 in 5
Fig 2. Proportion of individuals without treatment failure over the 48 study weeks by randomization arm in the (a) per protocol
population and (b) intention to treat population. Arm S = study arm (switch to maraviroc + darunavir/ritonavir); Arm C = continuation arm
(continuation of previous 3-drug therapy).
https://doi.org/10.1371/journal.pone.0187393.g002
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patients in arm S (1 uterine leiomyoma, 1 sub-ileus, 1 traumatic bone fracture, 1 urinary tract
infection, 1 syncope, 1 fibromyalgia) and 5 events in 4 patients in arm C (1 death for myocar-
dial infarction, 1 pericarditis, 1 traumatic bone fracture, 1 fever/chest pain, 1 prostatic adeno-
carcinoma). None of the serious adverse events was considered to be drug-related. Clinical
adverse events of grade 1 or 2 were 37 in 22 patients in arm S and 30 in 23 patients in arm C
(p = 0.27). No grade 3 clinical adverse event occurrred. Two events determined study discon-
tinuation at week 4 in arm S (asthenia and rash, both grade 1) and 10 in arm C (4 osteoporo-
sis at baseline, w4, w27, w48, 2 renal function deterioration at w4 and w12, diarrhoea at w24,
insomnia at w12, death for miocardial infarction at w12 and prostatic adenocarcinoma at
w36.
Twenty-eight (45%) and 14 (23%) patients in arm S and 24 (41%) and 19 (31%) in the arm
C experienced grade 3 and grade 4 laboratory toxicities, respectively, without significant differ-
ences between arms.
Changes in cd4 cell count, blood lipids and renal function
Changes in CD4 cell counts did not differ between the two study arms. At week 48, triglycer-
ides, total cholesterol, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cho-
lesterol did not show significant modifications (Fig 4a–4d). There were no differences in
changes from baseline eGFR between the 2 study arms at week 48 (mean -1 mL/min/1.73m2
in arm S, vs. -8 mL/min/1.73m2 in arm C, p = 0.12), although the study arm showed a better
preservation of kidney function from baseline between week 12 and 36 (at week 12 and 24
p = 0.004, at week 36 p = 0.034) (Fig 4e).
Table 2. Causes of treatment failure.
Per protocol population
DRV/r + MVC (Arm S)
n = 56
3-drug cART (Arm C)
n = 59
p-value
Any cause 16 (28.6) 24 (40.7) 0.238
Virological Failure 7 (12.5) 0 (0) 0.005
Adverse events (potentially treatment-
related)
2* (3.6) 8** (14.3) 0.095
Adverse events (all) 2 (3.6) 10 (16.9) 0.030
Withdrawal of consent/Patient’s choice 2 (3.6) 9 (16) 0.054
Loss to follow up 3 (5.4) 3 (5) 1.000
Other 2 (3.6) 2 (3.4) 1.000
Intention-to-treat population
DRV/r+ MVC (Arm S)
N = 62
3-drug cART (Arm C)
N = 61
p
Any cause 17 (27.4) 24 (39.3) 0.226
Virological Failure 8 (12.9) 0 (0) 0.006
Adverse events (potentially treatment-
related)
2* (3.2) 8** (13.1) 0.054
Adverse events (all) 2 (0) 10 (16.4) 0.016
Withdrawal of consent/Patient’s choice 2 (3.2) 9 (14.8) 0.030
Loss to follow up 3 (4.8) 3 (4.9) 1.000
Other 3 (4.8) 2 (3.3) 1.000
*1 Asthenia, 1 rash,
** 5 Osteoporosis/osteopenia, 2 creatinine increase, 1 diarrhea
https://doi.org/10.1371/journal.pone.0187393.t002
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Bone parameters
Changes in BMD and bone metabolism markers were evaluated in 64 patients: 34 in the S arm
and 30 in the C arm. At 48 weeks, patients in arm S showed significantly better gains over
those in arm C in femoral neck BMD (mean change +1.38% [SD 4.45%] in arm S vs -2.35%
[8.32%] in arm C, p = 0.04). Lumbar column BMD changes did not show significant differ-
ences between arms (at 48 weeks mean change from baseline +0.54% [8.09%] in arm S vs
-0.74% [6.32%] in arm C, p = 0.52). Patients in arm S showed a more prominent reduction of
total plasma alkaline phosphatase (-15.54 U/L [10.82 U/L] vs -1.45 U/L [13.36 U/L] in arm C,
p<0.001) and bone alkaline phosphatase (-9.10 μg/L [0.33 μg/L] vs -1.45 μg/L [4.69 μg/L] in
arm C, p = 0.19) at 48 weeks, compatible with a reduced bone remodeling. No other significant
changes were observed in the other bone metabolism biomarkers.
Drug levels, adherence, patient-reported symptoms and health-related
quality of life
One-hundred fourteen patients of the ITT population (62 in arm S, 52 in arm C) had at least
one assessment of self-reported adherence, patient-reported symptoms and QoL: baseline
Fig 3. Proportion of individuals with virological failure over the complete follow-up available until the time of
study interruption in the intention to treat population. Arm S = study arm (switch to maraviroc + darunavir/
ritonavir); Arm C = continuation arm (continuation of previous 3-drug therapy).
https://doi.org/10.1371/journal.pone.0187393.g003
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Fig 4. Evolution of (a-d) blood lipids and (e) renal function as by estimated GFR (CKD-EPI) over the 48
study weeks by randomization arm. Arm S = study arm (switch to maraviroc + darunavir/ritonavir); Arm
C = continuation arm (continuation of previous 3-drug therapy).
https://doi.org/10.1371/journal.pone.0187393.g004
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characteristics of these patients did not differ from those of the main stydy population (not
shown). Detailed numbers are reported in Table 3. Drug levels were measured in the 62
patients in arm S. In 8 patients Ctrough of all drugs at virological failure were significantly lower
as compared to those of patients without virological failure: darunavir median level 681 ng/mL
(IQR 0–1,589) vs 1,368 ng/mL (1,048–1,646), p = 0.038, maraviroc 36 ng/mL (7–152) vs 121
ng/mL (100–127), p<0.001, and ritonavir 2 ng/mL (0–81) vs 33 ng/mL (17–49), p<0.001.
Adherence, patient-reported symptoms, physical health or mental health-related QoL scores
did not differ between arms at baseline and at week 48 (Table 3). Physical health-related QoL
declined significantly from baseline to 48 weeks in arm C (63.64% vs 53.64%, p = 0.004) but
not in arm S (65.18% vs 58.33%, p = 0.26) (Table 3). Mean adherence was significantly lower
in patients during virological failure (arm S) and treatment failure (arm C) (Table 3). Among
patients with self-reported adherence80% in at least one determination, 5 of 30 (16.7%) in
arm S versus 0 of 21 (0%) in arm C showed virological failure (p = 0.049).
Discussion
This open-label randomized trial in virologically controlled patients on a 3-drug ART with R5
virus was designed to demonstrate the non-inferiority of switching therapy to once daily mara-
viroc plus ritonavir-boosted darunavir as compared to continuing the previous 3-drug regi-
men. Although the coadministration of once daily maraviroc 300 mg with darunavir/ritonavir
800/100 mg is not according to label, other studies demonstrated high tolerability and favour-
able pharmacokinetics when compared with 300 mg of maraviroc twice daily with 245 mg of
tenofovir/200 mg of emtricitabine [26]. The study was prematurely interrupted due to an
excess of virological failures in the dual therapy arm at week 48. The main study outcome, the
proportion without treatment failure at 48 weeks, did not differ between arms. Similarly, in a
Table 3. Adherence, health-related QoL and patient-reported symptoms at different time points, based on randomization arm.
DRV/rit + MVC (Arm S) 3-drug cART (Arm C) Between arm
comparisons
Baseline
(n = 34)
Week 48 (n = 34) P^ Baseline
(n = 27)
Week 48 (n = 27) P^ P
(baseline)
P (week
48)
Self reported adherence
(VAS 0–100%)
87.35%
(16.57)
87.35% (11.36) 1.00 88.88% (13.95) 89.63% (14.00) 0.80 0.70 0.48
Baseline
(n = 30)
Week 48 (n = 22) Baseline
(n = 30)
Week 48 (n = 22)
Patient-reported symptoms
score
1.39 (0.31) 1.44 (0.38) 0.21 1.41 (0.31) 1.36 (0.27) 0.35 0.80 0.42
Mental health QoL (VAS
0–100%)
62.07%
(25.54)
63.33% (22.48) 0.55 57.95% (22.34) 56.82% (25.79) 0.83 0.55 0.33
Physical health QoL (VAS
0–100%)
65.18%
(20.79)
58.33% (20.05) 0.26 63.64% (16.67) 53.64% (26.60) 0.04 0.78 0.47
At failure
(n = 8)*
During success***
(n = 129)
P At failure
(n = 12)**
During success***
(n = 108)
P
Self reported adherence
(VAS 0–100%)
73.3% (20) 88.2% (12.5) 0.001 80.8% (17.8) 89.23% (13.7) 0.05
Values indicate means (standard deviations). The symptoms score reports the sum of the values of the intensity of the symptom (from 1 = absent to 5 = very
much) divided by the number of evaluable symptoms per patient (max 30 total symptoms): adapted from ISS QoL [25].
^P-values of within-arm comparisons (week 48 vs baseline; success vs failure).
* In arm S all failures were virological;
** in arm C all failures were non-virological;
***instances with contemporary HIV RNA <50 copies/mL and no other cause of failure.
https://doi.org/10.1371/journal.pone.0187393.t003
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population of virologically suppressed patients, the MARCH study showed inferior efficacy of
maraviroc administered twice daily with one of several different bPIs as compared to continu-
ing 2 NRTIs plus bPI [18]. The present study and MARCH differ in patients treatment history,
PI types used, maraviroc dosing and virological outcomes definition, but both studies indicate
that maraviroc with bPI is inferior to standard 3-drug therapies in treatment experienced, viro-
logically suppressed patients. Both studies also complement results from the MODERN trial
showing inferior efficacy of maraviroc 150 mg qd as compared to tenofovir/emtricitabine,
both with darunavir/ritonavir in treatment naïve patients [15]. In order to explain the reason
for the excess of virological failures of this dual therapy regimen we examined a number of fac-
tors. At virological failure no case developed drug resistance and we found a single case of tro-
pism switch detected in viral DNA. Patients with virological failure had significantly lower
drug levels and a lower self-reported adherence. In addition, patients with 80% or lower adher-
ence in the S arm had 17% risk of virological failure, while no failures occurred in patients
with such low adherence levels in the C arm. Altogether this suggests a lower “forgiveness” of
the maraviroc plus darunavir/ritonavir regimen as compared to 3-drug ART, so that during
periods of suboptimal adherence, the insufficient drug exposure does not maintain virological
suppression.
For selecting candidate patients with R5-tropic virus we used a lower cut-off of the FPR of
the geno2pheno interpretation system (10%) than suggested by a European panel (20%) [19].
Notably, we found no correlation between this less stringent criterion and virological failure.
Indeed, virological failure was not associated with lower geno2pheno FPR at the screening
assay. All but one case of virological failure had FPR>60% at screening, which is associated
with very low rates of X4 or dual/mixed viral quasispecies [27], and the average FPR was actu-
ally higher in those failing than in those subsequently maintaining viral suppression. There-
fore, the choice of a single genotypic tropism assay with a geno2pheno FPR cut-off set at
10%, did not increase the risk of failure in this study. This finding, along with those from the
MARCH study [18], supports the use of a genotypic tropism assay on DNA for selecting viro-
logically suppressed patients to maraviroc.
Importantly, in line with the lack of drug resistance development, all patients with virologi-
cal rebound rapidly regained virological suppression with alternative therapies, showing that
effective therapeutic options were not lost in these cases. Of note, patients enrolled in this
study were more heavily pretreated and had lower nadir CD4 counts as patients enrolled in
bPI monotherapy studies, in more recent trials of maintenance therapy with bPI plus lamivu-
dine as well as in the MARCH study [11, 18, 28].
As mentioned, study and continuation arm did not differ in the primary efficacy endpoint
(proportion of patients free of treatment failure at 48 weeks on the per-protocol population).
Indeed, more patients in the continuation arm interrupted their regimen because of toxicity.
Most of these were renal or bone toxicities and were attributed to tenofovir disoproxil fuma-
rate, a member of the NRTI class, which was discontinued in all cases. While the open-label
study design could have facilitated treatment changes in the continuation arm, this did not
happen in the study arm with maraviroc and boosted darunavir, showing a good tolerability of
this regimen. In the subgroup of patients analyzed, BMD was improved in the study arm as
compared to the continuation arm and, accordingly, markers of bone turnover were also
improved. Altogether these findings suggest that the association of maraviroc 300 mg qd with
boosted darunavir qd is well tolerated and prevents some NRTI-associated toxicity. Candidate
patients should however be very carefully selected among those which guarantee the maximal
adherence levels and those with prolonged viral suppression. Alternatively, it should be tested
whether maintaining one of the less toxic NRTIs with this combination could be a virologically
safer strategy [29].
Switch to maraviroc with darunavir/r
PLOS ONE | https://doi.org/10.1371/journal.pone.0187393 November 21, 2017 13 / 18
The main limitation of this study is represented by the open label design, the heterogeneity
of the regimens in the continuation arm and the inclusion of less than half patients than
planned in the study. The reduced number of patients due to premature study discontinuation
did not allow us to formally conclude on the noninferiority of our experimental regimen on
the primary study outcome, although the lower 95% confidence interval bound of the differ-
ence between experimental and control arm was within the pre-specified lower margin for
defining noninferior efficacy. The heterogeneity of the comparator regimens allowed to com-
pare the efficacy of a drug reduction strategy against a number of different standard 3-drug
regimens which more closely reflect the reality of currently treated and virologically controlled
patients in clinical practice.
The inferior virologic efficacy of the dual regimen tested here contrasts with results
obtained with other dual regimens showing non-inferior efficacy to 3-drug therapy, in particu-
lar ritonavir-boosted PI regimens combined with lamivudine and dolutegravir with rilpivirine
[30–35]. Therefore, specific dual therapy approaches may be effective but MVC-based dual
therapies seem virologically inferior.
In conclusion, switching a standard 3-drug therapy to maraviroc 300 mg qd plus boosted
darunavir qd in virologically suppressed patients was associated with an improved tolerability
but was virologically inferior as compared to continuing the previous therapy. Virological fail-
ures were associated with lower adherence, which caused suboptimal drug exposure. Geno-
typic tropism testing on viral DNA can be employed to select virologically suppressed patients
to maraviroc but candidates to the dual therapy regimen tested here need to be carefully
selected and instructed.
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